EVI1, located at chromosome band 3q26, encodes a 1051 amino DNA-binding zinc fingers in the central part of the molecule.
We have recently found that EVI1 exists in two forms in scriptional activity of MDS1/EVI1 and EVI1, and we show that normal human tissues, and that one of the forms encodes a MDS1/EVI1 is a strong activator of promoters containing the AGATA motif, whereas EVI1 is a repressor. In addition, whereas
previously unreported longer open reading frame that includes EVI1 represses activation by the GATA-1 erythroid factor, 188 codons at the 5′ end of the gene. 12 About one third of the of EVI1. This region is also part of a gene, MDS1, which enOur results indicate that the rearrangements at 3q26 affect codes a small protein of about 20 kDa. 12 The longer form of expression of EVI1, but not of MDS1/EVI1. We propose that EVI1 containing MDS1 sequence was named MDS1/EVI1.
rearrangements at 3q26 involving EVI1 could result in leukemia
The novel amino terminal extension of EVI1 has strong homby a two-step process involving first transcriptional disruption of MDS1/EVI1, and next by inappropriately activating binds to the retinoblastoma protein and in the BLYMP1 gene, 12 important in B cell differentiation. The function of this conserved domain is not known. We have examined the funcIntroduction tion of this domain by using gene reporter assays and MDS1/EVI1 or EVI1 as effectors, and we have compared the The EVI1 gene, 1 located at chromosome band 3q26, is results to those obtained using GATA-1 as effector protein. As expressed in some tissues, and it is activated inappropriately a reporter gene, we used chloramphenicol acetyl transferase by chromosomal rearrangements involving band 3q26 in (CAT) linked to a human normal genomic promoter and to a about 2-5% of human myeloid leukemia with an abnormal synthetic promoter both of which have been previously karyotype. 2, 3 Expression of EVI1 in hematopoietic cells is condescribed. 11 Our results show that MDS1/EVI1 can activate troversial, but it has been reported for CD34
+ cells. 4 The most the promoters almost as strongly as GATA-1. Activation of the frequent rearrangements affecting EVI1 expression are promoters depends strictly on the segment of the PR domain t(3;3)(q21;q26) and inv(3)(q21q26), in which activation of encoded by the second and third untranslated exons of EVI1 EVI1 is due to juxtaposition of the gene to the enhancer region and on the first group of seven zinc fingers. Furthermore, actiof the ribophorin gene. 5 The gene can also be activated folvation by MDS1/EVI1 is repressed by expression of EVI1. To lowing the t(3;21)(q26;q22) in which EVI1 is fused downexamine the relative amounts of the two genes in the bone stream of the runt homology domain of the AML1 gene. 6, 7 In marrow, we have analyzed bone marrow samples of a normal addition, the gene can also be activated in cells with an apparindividual and of seven patients with the t(3;3) or the inv(3). ently normal karyotype by unknown mechanisms.
8 EVI1 is a Our results indicate that in some of the patients the rearrangenuclear protein containing a group of seven DNA-binding ments affect the expression of EVI1 but not MDS1/EVI1. These zinc fingers at the amino terminus and a second group of three results combined are especially important in view of the fact that recurring chromosomal translocations in leukemia with abnormalities at chromosome band 3q26 often disrupt the Binding reactions were done as described. 11 The products Plasmids pXMN-EVI1 and pXMN-GATA-1 used for expression of EVI1 and GATA-1 have been described.
11 Plasmid pBKof the binding reaction were separated by electrophoresis on a 5% non-denaturing polyacrylamide gel at 4°C. The gel was MDS1/EVI1 contains the cDNA of MDS1/EVI1 12 under the CMV promoter. The deletion mutant pBK-⌬MDS1/EVI1 was dried and exposed to X-ray film overnight. obtained by introduction of a stop codon at position 2832 of the published sequence. 12 This mutant lacks the second group of three zinc fingers and the carboxyl end. The reporter conReporter gene assays struct pTAK150-CAT is a derivative of pBLCAT and was obtained by insertion of the 207 bp of genomic fragment N 4 (AGATAN) 9 N 54 TTATCTN 88 , 11 upstream of the tk promoter. NIH-3T3 cells (0.5 × 10 6 cells per transfections) were transfected by calcium phosphate precipitation (Invitrogen). Cells The fragment contains nine tandem repeats of the sequence AGATA and a TTATCT 54 bp after the ninth tandem repeat.
were harvested 48 h post-transfection and cellular extracts were prepared and used immediately. Levels of CAT enzymes The two mutant promoters pTAK150.1-CAT and pTAK150.2-CAT were obtained by cloning two deletions of the genomic were determined by using ELISA detection kit (Boehringer Mannheim, Indianapolis, IN, USA) according to the manufacfragment consisting of either the nine tandem repeats (150.1CAT), or of the segment including nine tandem repeats turer's instructions. The efficiency of transfection was normalized after determination of the levels of ␤-gal, expressed and the TTATCT sequence as well (150.2CAT) in pBLCAT. The deletions were generated by polymerase chain reaction from plasmid pCH110 (Pharmacia, Washington, DC, USA). All measurements were done in quadruplicate. (PCR). After sequencing, the PCR-amplified fragments were 46,XX,−7,t(3;3)(q21;q26),der(7)t(1;7)(q32;q22)(87%) AML-M4/BM F/58 46,−7,t(3;3),t(3;7)(p12;p22),+der(7)(3%) 46,XX,del(11)(p13p15),t(3;3)(3%) 46,XX,−7,del(5)(q13q33),t(1;4)(p22;q31),t(3;3),+der(7)(3%) 45,XX,−7,−14,t(1;10)(q21;q23),t(3;3),+der (7) 
Results

Expression of MDS1/EVI1 and EVI1 in in vitro systems and in NIH-3T3 cells
We used the expression vector pBK-CMV to express MDS1, MDS1/EVI1 and the deletion mutant ⌬MDS1/EVI1 in NIH-3T3 cells. This vector contains the eukaryotic CMV promoter and the bacterial phage T3 promoter in the same orientation, so that the gene of interest can be translated in vitro and expressed in mammalian cells with the same recombinant plasmid. Unique bands corresponding to proteins of the predicted size were easily identified for each plasmid (not shown).
In addition, we also used Western blot analysis to detect EVI1 and MDS1/EVI1 in cellular extracts using anti-EVI1 rabbit antiserum. This antiserum recognizes both the MDS1/EVI1 and the EVI1 proteins. proximal zinc finger domain. 11 We expressed the proteins in
Western blot analysis Cos cells 0.4 × 10 6 were transfected with plasmids expressing MDS1/EVI1 or EVI1 using the calcium phosphate precipitate method. The cells were harvested 48 h post-transfection, resuspended in PBS buffer, and sonicated. After centrifugation, the supernatant was separated in a 8% SDS page gel. The proteins were transferred to a nylon membrane and incubated with anti-EVI1 antiserum. The bands were detected by chemoluminescence with the ECL kit (Amersham, Arlington Heights, IL, USA) according to manufacturer's instructions.
RNA isolation, reverse transcription-polymerase chain reaction, and standard Southern blot analysis the assays have been described. 6 vitro and used the reaction products for EMSA studies. The GATA-1. 11 To determine whether MDS1/EVI1 has similar effects as a transcriptional regulator, we performed a series of results are shown in Figure 3 . The unprogrammed lysate contained protein(s) that bound specifically to the probe (lane 2). transient transfections of NIH-3T3 cells using CAT as reporter gene. We initially used the plasmid pTAK150-CAT 11 containThe resulting DNA-protein complex could be disrupted by the addition of 100× cold probe (lane 3). Lanes containing lysate ing a 207 bp genomic fragment. This fragment was selected for its high binding affinity to the proximal group of zinc fingprogrammed with EVI1 (lane 4), MDS1/EVI1 (lane 6) or the deletion mutant ⌬MDS1/EVI1 (lane 8) showed additional ers of EVI1. It was previously shown that this genomic fragment acts as a promoter which can be activated by GATA-1, bands (indicated by arrows in Figure 3 ) corresponding to slower migrating complexes. The bands disappeared after whereas it is repressed by EVI1. 11 Figure 4 shows the results of the assays when we used MDS1/EVI1 as an effector of plasmid addition of cold competitor in excess, indicating that the binding of each protein to the probe was specific (lanes 5, 7 and pTAK150-CAT. The results indicate that MDS1/EVI1 can activate the promoter containing the 207 bp genomic fragment. 9). The results confirmed that the three proteins bound to the probe. In addition, we concluded that the binding was due to
Overall, the activation observed with MDS1/EVI1 was about 15-20% lower than for GATA-1. To determine whether the the proximal region of zinc fingers because this domain was present in all the three proteins, including the deletion activation required the presence of the distal group of zinc fingers or of the acidic domain, we used the deletion mutant mutant ⌬MDS1/EVI1. ⌬MDS1/EVI1 as effector plasmid. The results (Figure 4) show that these two domains are not required for transactivation of the promoter.
MDS1/EVI1 is a transcriptional activator
It was previously shown that EVI1 acts as a repressor of promoters containing the D1-CONS which can be activated by
The nine AGATA repeats at the promoter site sequence are sufficient for full activation by MDS1/EVI1
The 207 genomic fragment used as a promoter in the assays described above contains nine repeats of the 5-bp sequence 5′-AGATA-3′ at one end as well as an internal 5′-TTATCT-3′ sequence, 55 bp upstream of the repeat. 11 To determine whether the nine clustered repeats are sufficient for activation of the genomic promoter by MDS1/EVI1, we used the con- MDS1/EVI1 is a transcriptional activator. NIH-3T3 cells were transfected separately with 10 g of each plasmid DNA by the calcium phosphate precipitate method as indicated. Luciferase Figure 3 DNA-binding activity of EVI1 and MDS1/EVI1. Non-labeled in vitro translated proteins and 32 P-labeled probe were used for activity readings were normalized to relative expression of ␤-galactosidase and plotted as shown. Addition of GATA-1 gave consistently gel mobility shift assays in the presence (+) or absence (−) of 100 × cold competitor. Unprogrammed cell lysate was used as control the highest activation. Activation by MDS1/EVI1 was about 15-20% lower than with GATA-1. The distal domain of zinc finger did not (lanes 2 and 3) . Bands corresponding to slow migrating protein-probe complexes, indicated by the arrows, were observed when using the significantly change the activation of luciferase. EVI1 did not activate the promoter. Each value represents the average of at least four indein vitro translated proteins (lanes 4, 6 and 8) . The bands disappeared with the addition of cold competitor (lanes 5, 7 and 9). pendent measurements. structs pTAK150.1-CAT and pTAK150.2-CAT. These constructs were used in assays similar to those described in the previous section. Both promoters could activate the reporter gene, suggesting that the repeats are sufficient for full activation of the reporter gene. The results of the assays for plasmid pTAK150.1-CAT (containing the shorter promoter region) are shown in Figure 5 . To determine whether a smaller number of repeats can activate the promoter, we used the construct EVI1-consensus-CAT, which contains two copies of the D1-CONS upstream of the tk minimal promoter. This construct has been described previously.
11 No significant activation of the reporter gene was observed with this construct, suggesting that two repeats are not sufficient for activation of the promoter (data not shown).
MDS1/EVI1 is repressed by EVI1
Figure 6
EVI1 is a repressor of MDS1/EVI1. The promoter activation by GATA-1 and MDS1/EVI1 can be titrated by increasing
To determine whether EVI1 could act as a repressor of amounts of EVI1 (0 to 10 g, as indicated). The activation of the promoter in the absence of EVI1 is calculated as 100%.
MDS1/EVI1, we performed a series of transfection assays in which increasing amounts of EVI1 were added to a constant amount of MDS1/EVI1. We compared the results to those ing domain, we expressed it as a fusion protein with the DNAobtained using GATA-1 which can be repressed by increasing binding domain of Gal-4 (amino acids 1-147). We used this amounts of EVI1. 11 The results, shown in Figure 6 , indicate plasmid, pGal-4-PRD (Figure 1 ), as an effector to measure the that MDS1/EVI1 as well as GATA-1 can be repressed by EVI1.
activation of the CAT enzyme under the control of Gal-4 zinc Addition of MDS1/EVI1 to GATA-1 was additive, and resulted fingers. The results indicated that this domain by itself can act in a higher activation of the reporter gene (not shown). Thus, as a transcription activation domain, although not as strongly removal of the 188 amino acid extension at the N-terminus as MDS1/EVI1 (Figure 7) . To determine the region necessary can transform MDS1/EVI1 from a strong activator to a for activation, we used the plasmid pGal-4-MDS1 (Figure 1 ), repressor.
which lacks the segment encoded by the second and by half of the third exons of EVI1. Interestingly, this DNA region encodes a stretch of amino acids very rich in acidic residues,
The PR domain, but not MDS1, is a transcription activator domain
To determine whether the PR domain which does not contain any known DNA-binding motif can by itself act as an activat-
Figure 7
The activating region of MDS1/EVI1 resides in the PR domain. Two fusion proteins with the DNA-binding domain of Gal-4 were used in this assay: Gal4-PRD contains the entire PR domain, as indicated in Figure 1 . Gal4-MDS1 does not contain the acidic stretch of residues that are encoded by the second non-coding exon Figure 5 Nine AGATA repeats activate the promoter. A deletion mutant promoter containing only the nine AGATA repeats was actiand by the non-coding part of the third exon of EVI1 (Figure 1 ). No activation of the reporter gene was observed when using Gal4-MDS1 vated at levels comparable to the genomic promoter. Condition of transfections are described in the legend of Figure 4 .
as effector plasmid.
which are often present in transactivation domains. Plasmid altered by the breakpoint. The mechanisms by which EVI1 but not MDS1/EVI1 is activated in leukemia are very complex, pGal-4-MDS1 did not activate CAT significantly (Figure 7) , confirming that the acidic region is the part of the protein in that we see activation of EVI1, and normal low levels of MDS1/EVI1 in one of the patients with an inv(3) whom we necessary for the transactivating properties.
analyzed (Figure 8, lane 1) . As for other cases studied by other investigators for patients with the inv(3), we found by FISH analysis that the breakpoint in the inv(3) in this patient is 3′
Rearrangements at 3q26 affect EVI1 but not MDS1/EVI1 expression of EVI1, thus leaving the region between MDS1 and EVI1 apparently intact. In addition, patients with a normal karyotype may have overexpression of EVI1. A larger study is necesIt is well known that rearrangements at 3q26 often result in overexpression of EVI1. To determine whether the rearrangesary before any significant correlation can be made between the ratio of expression of the two genes and the location of ments affect expression of MDS1/EVI1 as well, we have analyzed the bone marrow of leukemia patients with rearrangethe breakpoint at 3q26. ments at 3q26 to determine the level of transcription of MDS1/EVI1 and of EVI1. We have used RT-PCR with primers which either identify the exon/exon junction between Discussion MDS1/EVI1, and therefore amplify this transcript, or which recognize the 3′ end of EVI1, and therefore amplify both EVI1 is a 1051 amino acid protein that has been extensively studied by a number of investigators because of its association MDS1/EVI1 and EVI1. After RT-PCR, the separated fragments were hybridized to internal oligomers as probes in Southern with myeloid leukemia when inappropriately expressed in humans, following chromosomal translocations, or in the blot analysis. The results for seven patients and one normal control are shown in Figure 8 , and indicate that the two genes, mouse, following retroviral insertion. [2] [3] [4] 14, 15 MDS1/EVI1 is a recently described protein that includes the entire EVI1, with very poorly expressed in normal bone marrow (Figure 8 , lane 4), are differentially expressed in some patients with 3q26 a unique additional extension of 188 amino acids at the Nterminus. This region has homology to the PR domain of the rearrangements. Whereas the level of MDS1/EVI1 is low in all eight samples analyzed, the level of EVI1 is very high in one RIZ and B-LYMP1 proteins but its function is unknown. The region encoding most of the 188 amino acids can also be (patient No. 1) of three patients with an inv(3) and in three (patient Nos 5, 7, 8) of four patients with a t(3;3) (Figure 8 ).
expressed as a gene separately from EVI1. We named this gene MDS1. 12 In addition to the region included in We had material for FISH analysis for two patients with the t(3;3), (Figure 8 , lanes 5 and 6). We could determine that in MDS1/EVI1, MDS1 contains at least two alternative 3′ translated exon(s) and two alternative 3′ untranslated regions. 12 By patient No. 5 the breakpoint was between the MDS1 and the EVI1 probes (centromeric to the MDS1 probe), therefore the using reporter gene assays in which CAT gene expression was controlled by a 207 bp genomic promoter containing nine breakpoint interrupts MDS1/EVI1 transcription. In the second case, in which we do not have overexpression of EVI1 AGATA repeats, it was previously shown that EVI1 is a repressor of the transactivator GATA- 1. 11 In this report we (Figure 8 , lane 6) the breakpoint was telomeric to the MDS1 probe, therefore the region between the two probes was not have used the same system to compare the transactivating properties of EVI1 and MDS1/EVI1 to those of GATA-1. Our results confirm that EVI1 represses activation by GATA-1. We also show that MDS1/EVI1 is a strong activator of the genomic promoter, and that addition of MDS1/EVI1 to GATA-1 will additively increase the level of gene expression rather than repress it as seen for EVI1. Thus, removal of the 188 amino acid N-terminal extension transforms MDS1/EVI1 from an activator to a repressor. Our results also show that the nine copies of the DNA repeat AGATA in the promoter region are sufficient for activation of the reporter gene. However, two copies of the repeats inserted upstream of the tk minimal promoter are not sufficient. Experiments using plasmids encoding the PR domain and MDS1 as fusion proteins with Gal-4 zinc fingers, indicate that the acidic 64 amino acid domain encoded by the second exon and by half of the third exon of EVI1 can act as a transactivator. It should be noted that these amino syndrome. As reported for the t(3;3), the t(3;21) and the
